BACKGROUND: Oncolytic viruses are among the most powerful and selective cancer therapeutics under development and are showing robust activity in clinical trials, particularly when administered directly into tumor nodules. However, their intravenous administration to treat metastatic disease has been stymied by unfavorable pharmacokinetics and inefficient accumulation in and penetration through tumors. METHODS: Adenovirus (Ad) was "stealthed" with a new N-(2-hydroxypropyl)methacrylamide polymer, and circulation kinetics were characterized in Balb/C SCID mice (n = 8 per group) bearing human ZR-75-1 xenograft tumors. Then, to noninvasively increase extravasation of the circulating polymer-coated Ad into the tumor, it was coinjected with gas microbubbles and the tumor was exposed to 0.5 MHz focused ultrasound at peak rarefactional pressure of 1.2 MPa. These ultrasound exposure conditions were designed to trigger inertial cavitation, an acoustic phenomenon that produces shock waves and can be remotely monitored in real-time. Groups were compared with Student t test or one-way analysis of variance with Tukey correction where groups were greater than two. All statistical tests were two-sided. RESULTS: Polymer-coating of Ad reduced hepatic sequestration, infection (>8000-fold; P < .001), and toxicity and improved circulation half-life (>50-fold; P = .001). Combination of polymer-coated Ad, gas bubbles, and focused ultrasound enhanced tumor infection >30-fold; (4 × 10(6) photons/sec/cm(2); standard deviation = 3 × 10(6) with ultrasound vs 1.3 × 10(5); standard deviation = 1 × 10(5) without ultrasound; P = .03) and penetration, enabling kill of cells more than 100 microns from the nearest blood vessel. This led to substantial and statistically significant retardation of tumor growth and increased survival. CONCLUSIONS: Combining drug stealthing and ultrasound-induced cavitation may ultimately enhance the efficacy of a range of powerful therapeutics, thereby improving the treatment of metastatic cancer.

Affiliations of authors Institute of Biomedical Engineering Department of Engineering Science

Zobrazit více v PubMed

Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6(8):879–885 PubMed

Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(2):101–117 PubMed

Peng Z, Yu Q, Bao L. The application of gene therapy in China. IDrugs. 2008;11(5):346–350 PubMed

Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113(9):1909–1918 PubMed PMC

Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006;14(1):118–128 PubMed

Danielsson A, Elgue G, Nilsson BM, et al. An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther. 2010;17(6):752–762 PubMed

Doronin K, Shashkova EV, May SM, et al. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20(9):975–988 PubMed PMC

Subr V, Kostka L, Selby-Milic T, et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release. 2009;135(2):152–158 PubMed

Wonganan P, Clemens CC, Brasky K, et al. Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus. Mol Pharm. 2011;8(1):78–92 PubMed PMC

Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11(16):1256–1263 PubMed

Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9(Suppl 5):10–17 PubMed

Vaupel P, Okunieff P, Neuringer LJ. Blood flow, tissue oxygenation, pH distribution, and energy metabolism of murine mammary adenocarcinomas during growth. Adv Exp Med Biol. 1989;248(1):835–845 PubMed

Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41(1):189–207 PubMed

Chen HH, Cawood R, El-Sherbini Y, et al. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther. 2011;19(1):67–75 PubMed PMC

Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22(1):276–284 PubMed

Tailor TD, Hanna G, Yarmolenko PS, et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther. 2010;9(6):1798–1808 PubMed PMC

Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–1454 PubMed

Gormley AJ, Larson N, Sadekar S, et al. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today. 2012;7(3):158–167 PubMed PMC

Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev .2010;62(3):284–304 PubMed PMC

Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst. 2007;99(14):1095–1106 PubMed

Mo S, Coussios CC, Seymour L, et al. Ultrasound-enhanced drug delivery for cancer. Expert Opin Drug Deliv. 2012;9(12):1525–1538 PubMed

Bazan-Peregrino M, Arvanitis CD, Rifai B, et al. Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model. J Control Release. 2012;157(2):235–242 PubMed

Arvanitis CD, Bazan-Peregrino M, Rifai B, et al. Cavitation-enhanced extravasation for drug delivery. Ultrasound Med Biol. 2011;37(11):1838–1852 PubMed

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther. 2008;19(9):873–886 PubMed

Ulbrich K, Subr V, Strohalm J, et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J Control Release. 2000;64(1–3):63–79 PubMed

Laga R, Carlisle R, Tangney M, et al. Polymer coatings for delivery of nucleic acid therapeutics. J Control Release. 2012;161(2):537–553 PubMed

Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8(23):1794–1800 PubMed PMC

Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol. 2005;79(23):14622–14631 PubMed PMC

Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3(5 Pt 1):708–722 PubMed

Miller DL, Thomas RM. Ultrasound contrast agents nucleate inertial cavitation in vitro. Ultrasound Med Biol. 1995;21(8):1059–1065 PubMed

Bazan-Peregrino M, Rifai B, Carlisle RC, et al. Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. J Control Release. 2013;169(1–2):40–47 PubMed

Green NK, Hale A, Cawood R, et al. Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine (Lond). 2012;7(11):1683–1695 PubMed

Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004;14(3):198–206 PubMed

Duan F, Simeone S, Wu R, et al. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J Immunol Methods. 2012;382(1–2):224–228 PubMed

Demers GW, Johnson DE, Tsai V, et al. Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Res. 2003;63(14):4003–4008 PubMed

Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–670 PubMed PMC

Bazan-Peregrino M, Carlisle RC, Purdie L, et al. Factors influencing retention of adenovirus within tumours following direct intratumoural injection. Gene Ther. 2008;15(9):688–694 PubMed

Wisse E, Jacobs F, Topal B, et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 2008;15(17):1193–1199 PubMed

Mace E, Montaldo G, Cohen I, et al. Functional ultrasound imaging of the brain. Nat Methods. 2011;8(8):662–664 PubMed

Greco A, Di Benedetto A, Howard CM, et al. Eradication of therapy- resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther. 2010;18(2):295–306 PubMed PMC

Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates